Amgen Issues Epogen and Procrit Recall
Amgen has issued Epogen and Procrit recall.
Today, Amgen issued a voluntary recall of 201 lots of Epogen and 155 lots of Procrit (epoitin alfa) because of concern about very thin glass flakes in the vials. The flakes, or lamellae, result from the interaction of the formulation with the glass vials over the shelf life of the product.
The company has announced that according to evaluations conducted by Amgen and Centocor, the risk to patients who have received product included in the recall is low. To date, there have been no complaints or adverse events reported which can be directly attributed to the presence of glass lamellae.
Epogen and Procrit are both manufactured by Amgen. Epogen is sold by Amgen in the United States. Centocor Ortho Biotech Products is the authorized distributor of Procrit in the United States.
Lists of the recalled product lots and expiration are available at at www.epogen.com and www.procrit.com.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
